CY2016009I2 - Ενωσεις για την αναστολη του ενζυμου πρωτεασωματος - Google Patents

Ενωσεις για την αναστολη του ενζυμου πρωτεασωματος

Info

Publication number: CY2016009I2
Authority: CY; Cyprus
Prior art keywords: inhibiting; compounds; proteasome enzyme; proteasome; enzyme
Prior art date: 2004-08-06

Application number

CY2016009C

Other languages

English (en)

Other versions

CY2016009I1 (el

Original Assignee

Onyx Therapeutics Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-08-06

Filing date

2016-04-22

Publication date

2016-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35502451&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2016009(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-04-22 Application filed by Onyx Therapeutics Inc. filed Critical Onyx Therapeutics Inc.

2016-08-31 Publication of CY2016009I1 publication Critical patent/CY2016009I1/el

2016-08-31 Publication of CY2016009I2 publication Critical patent/CY2016009I2/el

Links

102000004245 Proteasome Endopeptidase Complex Human genes 0.000 title 1
108090000708 Proteasome Endopeptidase Complex Proteins 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Psychiatry (AREA)
Physical Education & Sports Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Enzymes And Modification Thereof (AREA)

CY2016009C 2004-08-06 2016-04-22 Ενωσεις για την αναστολη του ενζυμου πρωτεασωματος CY2016009I2 (el)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US59940104P	2004-08-06	2004-08-06
US61000104P	2004-09-14	2004-09-14
US11/106,879 US7232818B2 (en)	2004-04-15	2005-04-14	Compounds for enzyme inhibition
PCT/US2005/028246 WO2006017842A1 (en)	2004-08-06	2005-08-08	Compounds for proteasome enzyme inhibition

Publications (2)

Publication Number	Publication Date
CY2016009I1 CY2016009I1 (el)	2016-08-31
CY2016009I2 true CY2016009I2 (el)	2016-08-31

Family

ID=35502451

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
CY20111100347T CY1116771T1 (el)	2004-08-06	2011-04-04	Ενωσεις για την αναστολη του ενζυμου πρωτεασωματος
CY2016009C CY2016009I2 (el)	2004-08-06	2016-04-22	Ενωσεις για την αναστολη του ενζυμου πρωτεασωματος
CY181100642T CY1120677T1 (el)	2004-08-06	2018-06-20	Ενωσεις για αναστολη ενζυμου πρωτεασωματος

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CY20111100347T CY1116771T1 (el)	2004-08-06	2011-04-04	Ενωσεις για την αναστολη του ενζυμου πρωτεασωματος

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CY181100642T CY1120677T1 (el)	2004-08-06	2018-06-20	Ενωσεις για αναστολη ενζυμου πρωτεασωματος

Country Status (25)

Country	Link
US (12)	US7232818B2 (el)
EP (4)	EP2266999B1 (el)
JP (2)	JP4743720B2 (el)
KR (3)	KR20130080064A (el)
CN (1)	CN102286070B (el)
AT (1)	ATE496062T1 (el)
AU (1)	AU2005271232B2 (el)
BR (2)	BRPI0514102B8 (el)
CA (1)	CA2589765C (el)
CY (3)	CY1116771T1 (el)
DE (1)	DE602005026019D1 (el)
DK (2)	DK3101026T3 (el)
ES (2)	ES2674277T3 (el)
FR (1)	FR16C0017I2 (el)
HK (4)	HK1103525A1 (el)
HU (2)	HUE038005T2 (el)
IL (3)	IL181127A (el)
LT (2)	LT3101026T (el)
LU (1)	LU93015I2 (el)
NO (2)	NO341015B1 (el)
PL (2)	PL3101026T3 (el)
PT (2)	PT1781688E (el)
SG (2)	SG155187A1 (el)
SI (2)	SI3101026T1 (el)
WO (1)	WO2006017842A1 (el)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7176232B2 (en)	2002-06-24	2007-02-13	The Regents Of The University Of California	Salinosporamides and methods for use thereof
CN103554222A (zh) *	2004-04-15	2014-02-05	欧尼斯治疗公司	用于抑制蛋白酶体酶的化合物
US8198270B2 (en) *	2004-04-15	2012-06-12	Onyx Therapeutics, Inc.	Compounds for proteasome enzyme inhibition
US7232818B2 (en) *	2004-04-15	2007-06-19	Proteolix, Inc.	Compounds for enzyme inhibition
WO2005111009A2 (en) *	2004-05-10	2005-11-24	Proteolix, Inc.	Synthesis of amino acid keto-epoxides
CN102875642A (zh) *	2004-05-10	2013-01-16	普罗特奥里克斯公司	用于酶抑制的化合物
DK1830838T3 (da)	2004-12-03	2013-01-21	Dana Farber Cancer Inst Inc	Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme
EP2260835B1 (en) *	2004-12-07	2013-03-06	Onyx Therapeutics, Inc.	Composition for proteasome inhibition
JP5436860B2 (ja)	2005-11-09	2014-03-05	オニキスセラピューティクス，インク．	酵素阻害のための化合物
KR101441703B1 (ko) *	2006-06-19	2014-09-17	오닉스 세라퓨틱스, 인크.	프로테아좀 저해를 위한 펩티드 에폭시케톤
US20090234150A1 (en) *	2006-07-14	2009-09-17	Peter Carmeliet	Use of ppar-alpha agonists to treat skeletal muscle wasting disorders
US7642369B2 (en) *	2006-09-12	2010-01-05	University Of Kentucky Research Foundation	Epoxyketone-based immunoproteasome inhibitors
US8367617B2 (en)	2007-10-04	2013-02-05	Onyx Therapeutics, Inc.	Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2013203566B2 (en) *	2007-10-04	2016-10-13	Onyx Therapeutics, Inc.	Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2016231532B2 (en) *	2007-10-04	2018-05-10	Onyx Therapeutics, Inc.	Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
US8394816B2 (en) *	2007-12-07	2013-03-12	Irene Ghobrial	Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
EP2088205A1 (en)	2008-02-11	2009-08-12	Institut National De La Sante Et De La Recherche Medicale (Inserm)	PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
US7635773B2 (en)	2008-04-28	2009-12-22	Cydex Pharmaceuticals, Inc.	Sulfoalkyl ether cyclodextrin compositions
WO2009140287A1 (en)	2008-05-12	2009-11-19	Nereus Pharmaceuticals, Inc.	Salinosporamide derivatives as proteasome inhibitors
AP2011005690A0 (en)	2008-10-21	2011-06-30	Onyx Therapeutics Inc	Combination therapy with peptide epoxyketones.
AR075899A1 (es)	2009-03-20	2011-05-04	Onyx Therapeutics Inc	Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
US20110009332A1 (en) *	2009-07-09	2011-01-13	Southwest Research Institute	Therapeutic Treatment Of Wounds
GB0914883D0 (en)	2009-08-26	2009-09-30	Univ Belfast	Compound
US8853147B2 (en)	2009-11-13	2014-10-07	Onyx Therapeutics, Inc.	Use of peptide epoxyketones for metastasis suppression
KR20130075723A (ko)	2010-03-01	2013-07-05	오닉스 세라퓨틱스, 인크.	면역프로테아좀 저해를 위한 화합물
EP2555621A4 (en)	2010-04-07	2014-07-02	Onyx Therapeutics Inc	CRYSTALLINE EPOXYCETONE PEPTIDE IMMUNOPROTEASOME INHIBITOR
US9126997B1 (en)	2010-09-07	2015-09-08	Northwestern University	Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
US9272014B2 (en)	2011-03-29	2016-03-01	Texas Tech University System	Galectin-3C combination therapy for human cancer
WO2013009923A1 (en) *	2011-07-13	2013-01-17	Creighton University	Methods of promoting neuron growth
CN104039328B (zh)	2011-11-11	2018-10-09	米伦纽姆医药公司	对蛋白酶体抑制剂的反应的生物标记
CN104126017A (zh)	2011-11-11	2014-10-29	米伦纽姆医药公司	对蛋白酶体抑制剂的反应的生物标记
CA2862492A1 (en)	2012-01-24	2013-08-01	Millennium Pharmaceuticals, Inc.	Methods of treatment of cancer
JP6508944B2 (ja)	2012-02-15	2019-05-08	サイデックス・ファーマシューティカルズ・インコーポレイテッド	シクロデキストリン誘導体のための製造方法
KR20190137963A (ko)	2012-05-08	2019-12-11	오닉스 세라퓨틱스, 인크.	펩티드 프로테아좀 억제제 제제화를 위한 사이클로덱스트린 복합체화 방법
EP2869820A4 (en) *	2012-07-09	2016-02-17	Onyx Therapeutics Inc	PRODRUGS OF PEPTIDEPOXIDE KETONE PROTEASE INHIBITORS
MX2015000813A (es)	2012-07-18	2015-09-07	Onyx Therapeutics Inc	Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
CA2881986A1 (en) *	2012-08-21	2014-02-27	Fluorinov Pharma Inc.	Fluorinated epoxyketone-based tetrapeptide compounds and uses thereof as proteasome inhibitors
CN105073785B (zh)	2012-10-22	2018-08-21	锡德克斯药物公司	烷基化环糊精组合物及其制备和使用方法
US20160022813A1 (en)	2013-03-13	2016-01-28	Sanofi	Compositions comprising anti-cd38 antibodies and carfilzomib
EA030957B1 (ru)	2013-03-14	2018-10-31	Оникс Терапьютикс, Инк.	Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы
AR095426A1 (es)	2013-03-14	2015-10-14	Onyx Therapeutics Inc	Inhibidores tripeptídicos de la epoxicetona proteasa
MX2016000568A (es)	2013-07-19	2016-08-01	Onyx Therapeutics Inc	Inhibidores de proteasoma de epoxicetona peptídica en combinacion con inhibidores de cinasa pim para el tratamiento de canceres.
CN103360348B (zh) *	2013-07-25	2015-06-24	苏州鹏旭医药科技有限公司	一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法
CN105517998A (zh) *	2013-09-06	2016-04-20	桑多斯股份公司	通过曼尼希反应立体选择性合成二醇和三醇以及它们在卡非佐米合成中的用途
CA2920220A1 (en) *	2013-09-06	2015-03-12	Sandoz Ag	Synthesis of peptide epoxy ketones
WO2015121769A1 (en)	2014-02-13	2015-08-20	Ranbaxy Laboratories Limited	Process for the preparation of methyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phenylalaninate
CN103864889B (zh) *	2014-04-04	2017-01-11	重庆泰濠制药有限公司	环氧酮化合物、其制备方法及卡非佐米的制备方法
PT3183295T (pt)	2014-08-22	2023-11-03	Cydex Pharmaceuticals Inc	Composições de ciclodextrina alquilada fracionada e processos para preparação e utilização das mesmas
WO2016046843A1 (en)	2014-09-24	2016-03-31	Biophore India Pharmaceuticals Pvt. Ltd.	Process for the preparation of (s)-4-methyl-n-((s)-1-(((s)-4-methyl-1-((r)-2-methyloxiran-2-yl)-1-oxo pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide
WO2016069479A1 (en)	2014-10-27	2016-05-06	Apicore Us Llc	Methods of making carfilzomib and intermediates thereof
CN104402973A (zh) *	2014-11-24	2015-03-11	重庆泰濠制药有限公司	一种卡非佐米无定型晶的制备方法
US10253066B2 (en)	2014-12-02	2019-04-09	Fresenius Kabi Oncology Limited	Process for purification of Carfilzomib
EP3240575A4 (en)	2014-12-31	2018-07-25	Dr. Reddy's Laboratories Ltd.	Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib
US10544189B2 (en)	2015-04-22	2020-01-28	Msn Laboratories Private Limited	Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide
WO2016185450A1 (en)	2015-05-21	2016-11-24	Laurus Labs Private Limited	An improved processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
CN106317188A (zh) *	2015-06-18	2017-01-11	重庆医药工业研究院有限责任公司	一种制备卡非佐米无定型物的方法
WO2017032487A1 (en)	2015-08-27	2017-03-02	Technische Universität München	Proteasome inhibitor comprising a signal-emitting moiety
WO2017098532A1 (en)	2015-12-11	2017-06-15	Mylan Laboratories Limited	Crystalline and amorphous forms of carfilzomib
TWI636052B (zh) *	2015-12-31	2018-09-21	中化合成生技股份有限公司	無定形卡非佐米(i)的製備方法
WO2017147410A1 (en)	2016-02-25	2017-08-31	Amgen Inc.	Compounds that inhibit mcl-1 protein
TWI759301B (zh)	2016-05-24	2022-04-01	美商安美基公司	聚乙二醇化卡非佐米化合物
WO2018024645A1 (en)	2016-08-02	2018-02-08	Synthon B.V.	Process for making carfilzomib
MX2019001459A (es)	2016-08-05	2019-06-20	Amgen Inc	Sintesis de (s)-2-amino-4-metil-1-((r)-2-metiloxirano-2-il)-pentan -1-ona y sales farmacuticamente aceptables de la misma.
ES2874683T3 (es)	2016-09-14	2021-11-05	Fresenius Kabi Oncology Ltd	Un proceso para la purificación de un intermedio de carfilzomib
WO2018050656A2 (en)	2016-09-16	2018-03-22	Hsf Pharmaceuticals	Inhibitors of heat shock factors and uses thereof
EP3330260A1 (en)	2016-12-01	2018-06-06	Enantia, S.L.	Process for the preparation of an intermediate for the synthesis of i.a. carfilzomib
CA3075714A1 (en)	2017-09-14	2019-03-21	Glaxosmithkline Intellectual Property Development Limited	Combination treatment for cancer
JP2021503441A (ja)	2017-11-16	2021-02-12	アムジエン・インコーポレーテツド	Ｐｅｇ化されたカルフィルゾミブ化合物の安定組成物
CN111699386B (zh) *	2017-12-08	2023-08-18	神经Gx有限责任公司	用于阿尔茨海默病的同步化细胞周期基因表达测试及相关治疗方法
US10537585B2 (en)	2017-12-18	2020-01-21	Dexcel Pharma Technologies Ltd.	Compositions comprising dexamethasone
US10689416B2 (en)	2017-12-30	2020-06-23	Unity Biotechnology, Inc.	Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
WO2019133988A1 (en)	2017-12-30	2019-07-04	Unity Biotechnology, Inc.	Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
SG11202012765PA (en) *	2018-06-22	2021-01-28	Ucl Business Ltd	Novel compounds
EP4041747A4 (en) *	2019-10-11	2023-10-18	Mayo Foundation for Medical Education and Research	PROTEASOME INHIBITORS
WO2023220641A2 (en)	2022-05-11	2023-11-16	Juno Therapeutics, Inc.	Methods and uses related to t cell therapy and production of same
WO2023220655A1 (en)	2022-05-11	2023-11-16	Celgene Corporation	Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2024069240A2 (en)	2022-09-29	2024-04-04	Takeda Pharmaceutical Company Limited	Cd38-binding fusion protein combination therapy
WO2024097905A1 (en)	2022-11-02	2024-05-10	Celgene Corporation	Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
CN116768972A (zh) *	2023-06-25	2023-09-19	重庆药友制药有限责任公司	一种卡非佐米中间体的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US569748A (en)		1896-10-20		Henry edmunds
US4733665C2 (en)	1985-11-07	2002-01-29	Expandable Grafts Partnership	Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5071957A (en)	1989-08-04	1991-12-10	Bristol-Myers Company	Antibiotic BU-4061T
US4990448A (en)	1989-08-04	1991-02-05	Bristol-Myers Company	Bu-4061T
US5340736A (en)	1991-05-13	1994-08-23	The President & Fellows Of Harvard College	ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
AU4499697A (en)	1996-09-13	1998-04-02	New York University	Method for treating parasitic diseases with proteasome inhibitors
US6099851A (en) *	1998-06-02	2000-08-08	Weisman; Kenneth M.	Therapeutic uses of leuprolide acetate
US6902721B1 (en)	1998-07-10	2005-06-07	Osteoscreen, Inc.	Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en)	1998-07-10	2002-10-08	Osteoscreen, Inc.	Inhibitors of proteasomal activity and production for stimulating bone growth
US6838436B1 (en)	1998-07-10	2005-01-04	Osteoscreen Inc.	Inhibitors of proteasomal activity for stimulating bone growth
US6204257B1 (en)	1998-08-07	2001-03-20	Universtiy Of Kansas	Water soluble prodrugs of hindered alcohols
US6492333B1 (en)	1999-04-09	2002-12-10	Osteoscreen, Inc.	Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6831099B1 (en)	1999-05-12	2004-12-14	Yale University	Enzyme inhibition
JP2003528039A (ja)	1999-10-20	2003-09-24	オステオスクリーン，インコーポレイテッド	骨および毛成長を刺激するためのプロテアソーム活性のインヒビター
EP1463719A2 (en)	2002-01-08	2004-10-06	Eisai Co., Ltd	Eponemycin and epoxomicin analogs and uses thereof
US7232818B2 (en)	2004-04-15	2007-06-19	Proteolix, Inc.	Compounds for enzyme inhibition
CN103554222A (zh) *	2004-04-15	2014-02-05	欧尼斯治疗公司	用于抑制蛋白酶体酶的化合物
WO2005111009A2 (en)	2004-05-10	2005-11-24	Proteolix, Inc.	Synthesis of amino acid keto-epoxides
CN102875642A (zh)	2004-05-10	2013-01-16	普罗特奥里克斯公司	用于酶抑制的化合物

2005
- 2005-04-14 US US11/106,879 patent/US7232818B2/en active Active
- 2005-08-08 SG SG200905204-4A patent/SG155187A1/en unknown
- 2005-08-08 AT AT05784484T patent/ATE496062T1/de active
- 2005-08-08 SG SG10201701794UA patent/SG10201701794UA/en unknown
- 2005-08-08 ES ES16166492.5T patent/ES2674277T3/es active Active
- 2005-08-08 EP EP10012498.1A patent/EP2266999B1/en active Active
- 2005-08-08 PT PT05784484T patent/PT1781688E/pt unknown
- 2005-08-08 JP JP2007525077A patent/JP4743720B2/ja active Active
- 2005-08-08 EP EP05784484A patent/EP1781688B1/en active Active
- 2005-08-08 DE DE602005026019T patent/DE602005026019D1/de active Active
- 2005-08-08 EP EP10012497.3A patent/EP2270026B1/en active Active
- 2005-08-08 EP EP16166492.5A patent/EP3101026B1/en active Active
- 2005-08-08 US US11/199,899 patent/US7417042B2/en active Active
- 2005-08-08 LT LTEP16166492.5T patent/LT3101026T/lt unknown
- 2005-08-08 KR KR1020137016063A patent/KR20130080064A/ko not_active Application Discontinuation
- 2005-08-08 BR BRPI0514102A patent/BRPI0514102B8/pt active IP Right Grant
- 2005-08-08 SI SI200532211T patent/SI3101026T1/en unknown
- 2005-08-08 AU AU2005271232A patent/AU2005271232B2/en active Active
- 2005-08-08 PL PL16166492T patent/PL3101026T3/pl unknown
- 2005-08-08 HU HUE16166492A patent/HUE038005T2/hu unknown
- 2005-08-08 CA CA2589765A patent/CA2589765C/en active Active
- 2005-08-08 DK DK16166492.5T patent/DK3101026T3/en active
- 2005-08-08 ES ES10012498.1T patent/ES2525248T3/es active Active
- 2005-08-08 CN CN201110145272.7A patent/CN102286070B/zh active Active
- 2005-08-08 PL PL05784484T patent/PL1781688T3/pl unknown
- 2005-08-08 SI SI200531264T patent/SI1781688T1/sl unknown
- 2005-08-08 KR KR1020077003533A patent/KR101354280B1/ko active Protection Beyond IP Right Term
- 2005-08-08 WO PCT/US2005/028246 patent/WO2006017842A1/en active Application Filing
- 2005-08-08 PT PT161664925T patent/PT3101026T/pt unknown
- 2005-08-08 BR BR122020008634A patent/BR122020008634B8/pt active IP Right Grant
- 2005-08-08 DK DK05784484.7T patent/DK1781688T3/da active
- 2005-08-08 KR KR1020127030701A patent/KR101544258B1/ko active Protection Beyond IP Right Term
2007
- 2007-02-01 IL IL181127A patent/IL181127A/en active Protection Beyond IP Right Term
- 2007-02-20 NO NO20070965A patent/NO341015B1/no unknown
- 2007-04-11 US US11/786,217 patent/US7491704B2/en active Active
- 2007-11-07 HK HK07112064.9A patent/HK1103525A1/xx unknown
2011
- 2011-03-04 JP JP2011047047A patent/JP5394423B2/ja active Active
- 2011-04-04 CY CY20111100347T patent/CY1116771T1/el unknown
- 2011-06-29 HK HK11106710A patent/HK1152536A1/xx unknown
- 2011-07-04 HK HK11106767.5A patent/HK1152716A1/zh unknown
2012
- 2012-08-22 IL IL221572A patent/IL221572B/en active IP Right Grant
2014
- 2014-08-06 US US14/452,844 patent/US20140342977A1/en not_active Abandoned
2015
- 2015-08-26 US US14/835,876 patent/US20150361134A1/en not_active Abandoned
2016
- 2016-04-05 HU HUS1600014C patent/HUS1600014I1/hu unknown
- 2016-04-06 LU LU93015C patent/LU93015I2/xx unknown
- 2016-04-08 US US15/094,088 patent/US20160222057A1/en not_active Abandoned
- 2016-04-12 LT LTPA2016010C patent/LTC1781688I2/lt unknown
- 2016-04-22 CY CY2016009C patent/CY2016009I2/el unknown
- 2016-05-12 FR FR16C0017C patent/FR16C0017I2/fr active Active
2017
- 2017-03-14 NO NO20170381A patent/NO344397B1/no unknown
- 2017-05-18 HK HK17105016.0A patent/HK1231491A1/zh unknown
2018
- 2018-02-13 US US15/895,120 patent/US20180170962A1/en not_active Abandoned
- 2018-06-20 CY CY181100642T patent/CY1120677T1/el unknown
- 2018-09-20 IL IL261892A patent/IL261892B/en active IP Right Grant
2019
- 2019-03-13 US US16/351,669 patent/US20190211058A1/en not_active Abandoned
- 2019-10-31 US US16/669,601 patent/US20200071356A1/en not_active Abandoned
2020
- 2020-06-26 US US16/912,806 patent/US20200325172A1/en not_active Abandoned
2021
- 2021-02-08 US US17/169,990 patent/US20210179663A1/en not_active Abandoned
2022
- 2022-04-29 US US17/733,077 patent/US20220267372A1/en not_active Abandoned

Also Published As

Publication number	Publication date
SG10201701794UA (en)	2017-04-27
JP2008509166A (ja)	2008-03-27
NO20170381A1 (no)	2007-04-16
NO341015B1 (no)	2017-08-07
US20160222057A1 (en)	2016-08-04
KR20070047780A (ko)	2007-05-07
LTC1781688I2 (lt)	2017-09-25
NO20070965L (no)	2007-04-16
HK1152716A1 (zh)	2012-03-09
US7417042B2 (en)	2008-08-26
CN102286070B (zh)	2014-12-10
LT3101026T (lt)	2018-07-10
EP2266999A2 (en)	2010-12-29
HK1103525A1 (en)	2007-12-21
JP4743720B2 (ja)	2011-08-10
US7491704B2 (en)	2009-02-17
EP2270026B1 (en)	2016-05-18
CA2589765A1 (en)	2006-02-16
AU2005271232A1 (en)	2006-02-16
EP1781688B1 (en)	2011-01-19
US20140342977A1 (en)	2014-11-20
LU93015I2 (fr)	2016-06-06
US20060030533A1 (en)	2006-02-09
CY2016009I1 (el)	2016-08-31
BR122020008634B8 (pt)	2021-07-27
WO2006017842A1 (en)	2006-02-16
ES2674277T3 (es)	2018-06-28
IL221572A0 (en)	2012-10-31
DK1781688T3 (da)	2011-03-14
EP3101026B1 (en)	2018-03-28
BRPI0514102B1 (pt)	2020-07-07
PT1781688E (pt)	2011-04-05
US20220267372A1 (en)	2022-08-25
US20150361134A1 (en)	2015-12-17
US20050245435A1 (en)	2005-11-03
US7232818B2 (en)	2007-06-19
PT3101026T (pt)	2018-08-03
CA2589765C (en)	2015-06-30
IL261892A (en)	2018-10-31
HUE038005T2 (hu)	2018-09-28
EP3101026A1 (en)	2016-12-07
BRPI0514102A (pt)	2008-05-27
DK3101026T3 (en)	2018-06-18
CY1116771T1 (el)	2016-08-31
EP2266999B1 (en)	2014-09-24
US20190211058A1 (en)	2019-07-11
KR20130080064A (ko)	2013-07-11
KR101544258B1 (ko)	2015-08-21
DE602005026019D1 (de)	2011-03-03
SI1781688T1 (sl)	2011-05-31
SI3101026T1 (en)	2018-08-31
US20180170962A1 (en)	2018-06-21
IL181127A0 (en)	2007-07-04
US20200071356A1 (en)	2020-03-05
EP1781688A1 (en)	2007-05-09
HUS1600014I1 (hu)	2016-05-30
PL3101026T3 (pl)	2018-12-31
FR16C0017I2 (fr)	2016-08-26
NO344397B1 (no)	2019-11-25
CY1120677T1 (el)	2019-12-11
LTPA2016010I1 (lt)	2016-04-25
ATE496062T1 (de)	2011-02-15
KR101354280B1 (ko)	2014-01-23
BRPI0514102B8 (pt)	2021-05-25
EP2270026A2 (en)	2011-01-05
JP2011148805A (ja)	2011-08-04
PL1781688T3 (pl)	2011-06-30
US20070191284A1 (en)	2007-08-16
HK1152536A1 (en)	2012-03-02
HK1231491A1 (zh)	2017-12-22
AU2005271232B2 (en)	2012-07-05
JP5394423B2 (ja)	2014-01-22
ES2525248T3 (es)	2014-12-19
BR122020008634B1 (pt)	2021-02-17
IL221572B (en)	2018-10-31
KR20120135355A (ko)	2012-12-12
IL261892B (en)	2019-12-31
IL181127A (en)	2013-03-24
EP2266999A3 (en)	2011-09-14
CN102286070A (zh)	2011-12-21
SG155187A1 (en)	2009-09-30
EP2270026A3 (en)	2011-09-14
FR16C0017I1 (el)	2016-06-24
US20200325172A1 (en)	2020-10-15
US20210179663A1 (en)	2021-06-17

Publication	Publication Date	Title
CY2016009I1 (el)	2016-08-31	Ενωσεις για την αναστολη του ενζυμου πρωτεασωματος
DK2030981T3 (da)	2014-10-13	Forbindelser til proteasom-enzymhæmning
HK1220208A1 (zh)	2017-04-28	用於酶抑制的化合物
ATE435198T1 (de)	2009-07-15	Orthosubstituierte aryl- oder heteroarylamidverbindungen
ITMI20042238A1 (it)	2005-02-19	Composti per fluoropolirterei
SI1745064T1 (sl)	2011-05-31	Spojine za inhibiranje proteasomskega encima
DE602005000799D1 (de)	2007-05-16	Flanschstruktur
ATE384719T1 (de)	2008-02-15	Dioxazinyl-substituierte thienylsulfonylaminocarbonylverbindungen
SE0402103D0 (sv)	2004-08-30	Novel compounds
SE0400022D0 (sv)	2004-01-08	New compounds
DK2260835T3 (da)	2013-06-03	Sammensætning til proteasominhibering
ATA6292004A (de)	2005-11-15	Abdeckplatte
SE0400254D0 (sv)	2004-02-06	New compounds
NO20043762L (no)	2006-03-09	Fôr
NO20041954D0 (no)	2004-05-12	Fôr
DOP2004000959A (es)	2005-01-31	Compuestos
SE0402391D0 (sv)	2004-10-04	Novelheterocyclic compounds
SE0402068D0 (sv)	2004-08-24	Novel compounds
SE0402069D0 (sv)	2004-08-24	Novel compounds
SE0400286D0 (sv)	2004-02-11	Novel Compounds
SE0401885D0 (sv)	2004-07-19	Novel compounds
SE0403054D0 (sv)	2004-12-15	Novel compounds
SE0401348D0 (sv)	2004-05-26	Novel compounds
ITLU20050018A1 (it)	2006-12-23	Copertura per gronde
SI1948678T1 (sl)	2013-08-30	Spojine za inhibiranje encimov